LAURA DOUGLASS
Prescription History 1902148596
Urology in Philadelphia, PA


Quality Rating: 76.7 out of 100 score

NPI Status: Active since March 21, 2013

Contact Information

3509 N BROAD ST
PHILADELPHIA, PA
ZIP 19140
Phone: (215) 707-3375
Fax: (215) 707-4758

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for LAURA DOUGLASS, an active Urology specialist practicing in Philadelphia, PA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 325 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 148 claims alone.

Medication Index

No matching medications currently found on file.

Estradiol

Generic Formulation: EstradiolSpecialty: Urology
Provider Metrics Summary
Total Claims 69
30-Day Fills 77.0
Days Supply 2,198
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills73.8
Peer Average Days Supply2,193
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 115.6% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,475.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$122.84

State Avg Cost Per Claim

$104.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Finasteride

Generic Formulation: FinasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 42
30-Day Fills 78.0
Days Supply 2,340
PA State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills128.1
Peer Average Days Supply3,757
Conservative Utilization

This provider writes prescriptions for this formulation 27.6% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $380.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.05

State Avg Cost Per Claim

$16.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Gemtesa

Generic Formulation: VibegronSpecialty: Urology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
PA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills45.2
Peer Average Days Supply1,244
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,414.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$470.73

State Avg Cost Per Claim

$554.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Urology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
PA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply1,827
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,429.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$449.05

State Avg Cost Per Claim

$554.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 148
30-Day Fills 216.0
Days Supply 6,480
PA State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills185.5
Peer Average Days Supply5,393
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.9% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,997.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.50

State Avg Cost Per Claim

$19.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Trospium Chloride

Generic Formulation: Trospium ChlorideSpecialty: Urology
Provider Metrics Summary
Total Claims 25
30-Day Fills 33.0
Days Supply 990
PA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills43.0
Peer Average Days Supply1,245
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,970.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.83

State Avg Cost Per Claim

$62.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like LAURA DOUGLASS provides transparency into local medical care patterns within Philadelphia, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.